| Study of ESG401 in Adults With Solid Tumors (NCT04892342) | Shanghai Escugen Biotechnology Co., Ltd | 2021-09-14 |
| Endoscopic Mucosal Resection Versus Endoscopic Submucosal Dissection for Colorectal Laterally Spreading Lesions. (NCT04593407) | José Carlos Marín Gabriel | 2020-11-03 |
| Self-expandable Metal Stent (SEMS) Endoscopic Placement for Malignant Colonic Obstruction Therapy (NCT05643989) | Russian Society of Colorectal Surgeons | 2019-11-01 |
| Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement (NCT06118125) | University of Bordeaux | 2019-06-01 |
| 9-ING-41 in Patients With Advanced Cancers (NCT03678883) | Actuate Therapeutics Inc. | 2019-01-04 |
| A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (NCT03428958) | NuCana plc | 2018-10-05 |
| A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway (NCT02395224) | Norwegian University of Science and Technology | 2014-09-01 |
| A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer (NCT02176746) | Fuda Cancer Hospital, Guangzhou | 2014-06-01 |
| Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI) (NCT01671592) | Pawel Kalinski | 2013-01-01 |
| Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer (NCT01545141) | Roswell Park Cancer Institute | 2012-10-01 |
| A Trial of Glutamine to Prevent Oxaliplatin Neurotoxicity and a Pharmacokinetic Analysis of Oxaliplatin (NCT01157039) | AHS Cancer Control Alberta | 2011-10-01 |
| Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer (NCT02321969) | Seoul National University Hospital | 2010-08-01 |
| Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer (NCT01139138) | The Queen Elizabeth Hospital | 2010-06-01 |
| Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy (NCT00967616) | Daiichi Sankyo | 2009-09-01 |
| Nelfinavir, a Phase I/Phase II Rectal Cancer Study (NCT00704600) | Maastricht Radiation Oncology | 2008-09-01 |
| A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects With Colorectal Cancer and Hepatic Metastases (NCT00920803) | Sirtris, a GSK Company | 2008-08-19 |
| Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer (NCT00536809) | GlaxoSmithKline | 2007-09-26 |
| Study of Pazopanib, Irinotecan and Cetuximab in Combination to Treat 2nd Line Metastatic Colorectal Cancer (NCT00540943) | GlaxoSmithKline | 2007-07-13 |
| A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer (NCT00478634) | Novartis Pharmaceuticals | 2007-05-01 |
| Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin) (NCT00387387) | GlaxoSmithKline | 2006-10-20 |